Key Highlights

● Strata Skin Sciences confirmed its Nasdaq delisting and announced plans to go dark, fully deregistering from its ongoing SEC reporting obligations.

● The company confirmed the delisting in a press release dated around February 19-20, 2026, following an earlier Nasdaq compliance extension it was ultimately unable to sustain.

● Going dark represents a considerably more complete Withdrawal from public markets than a typical delisting to over-the-counter trading with continued SEC reporting alone.

● The company develops and markets dermatology medical devices, including excimer laser and light-based systems for treating skin conditions such as psoriasis and vitiligo.

Strata Skin Sciences (OTC:SSKN) has confirmed its Nasdaq delisting and announced plans to go dark, meaning the dermatology device maker will both leave the exchange and fully deregister from its ongoing SEC reporting obligations, a considerably more complete withdrawal from public markets than a typical delisting to over-the-counter trading alone would be. The company confirmed the delisting in a press release dated around February 19-20, 2026, following an earlier period in which the company had disclosed receiving a Nasdaq compliance extension before ultimately being unable to sustain full compliance.

Business Overview

Strata Skin Sciences develops and markets medical devices used in dermatology, including excimer laser and light-based systems for treating skin conditions such as psoriasis and vitiligo, positioning the company within the health technology sector as a specialist device manufacturer serving dermatology practices and clinics.

The decision to go dark, rather than simply moving to over-the-counter trading while remaining an SEC-reporting company, represents a more significant withdrawal from public markets, since deregistration eliminates the ongoing periodic disclosure obligations that even most OTC-traded companies typically maintain. Excimer laser and light-based dermatology devices compete in a specialist medical device niche where regulatory clearance, clinical evidence and ongoing physician relationships all matter considerably more than broad consumer brand recognition.

Latest Development

The most recent verified development is the confirmed Nasdaq delisting and go-dark announcement itself, which followed the company's earlier disclosure of a Nasdaq compliance extension, indicating Strata had been granted additional time to address its listing-standards shortfall before ultimately concluding that continuing to pursue compliance, or an over-the-counter listing with continued SEC reporting, was simply not the path forward it chose to take.

Financial and Sector Context

A company choosing to go dark rather than pursue continued OTC trading with SEC reporting typically does so to eliminate the ongoing costs of public-company compliance, including audit, legal and periodic filing expenses, when management ultimately concludes those costs are no longer justified by the benefits of maintaining any kind of public trading market for the shares. The near-zero share price and thin market Capitalization are consistent with a company that had already experienced substantial value erosion well prior to this final step.

Risks

The genuinely significant loss of transparency that accompanies any go-dark decision of this kind is a material risk, since shareholders who retain their stock will have access to considerably less information about the company's ongoing operations and financial condition than they did while it remained an SEC-reporting company. Any residual trading in the shares is likely to occur, if it continues at all, on the least regulated and least transparent tiers of the over-the-counter market.

Deregistration Marks a Near-Total Exit

Readers should watch for any final disclosure Strata Skin Sciences makes before fully completing its deregistration process, confirmation of whether and how the shares continue to trade following the go-dark decision, and any indication of the company's plans for its underlying dermatology device Business and assets.